{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:21:08Z","timestamp":1777879268762,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bulcan.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:09:25Z","timestamp":1773936565000},"page":"654-663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Actualit\u00e9s et synth\u00e8se du traitement de seconde ligne des CBNPC de stade IV sans addiction oncog\u00e9nique"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-7413","authenticated-orcid":false,"given":"Thomas","family":"Pierret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Descourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Corre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bulcan.2026.02.003_bib0180","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.02.003_bib0185","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.02.003_bib0190","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.003_bib0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2026.02.003_bib0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2020.02.022","article-title":"Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: results of the IFCT-1103 ULTIMATE study","volume":"131","author":"Cortot","year":"2020","journal-title":"Eur J Cancer"},{"issue":"9944","key":"10.1016\/j.bulcan.2026.02.003_bib0205","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.003_bib0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.003_bib0215","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2014.03.026","article-title":"Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials","volume":"85","author":"Zhao","year":"2014","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.003_bib0220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.31105","article-title":"Immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.003_bib0225","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/j.cllc.2020.04.013","article-title":"Immune checkpoint inhibitors rechallenge efficacy in non-small-cell lung cancer patients","volume":"21","author":"Gobbini","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2026.02.003_bib0230","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann Oncol [Internet]"},{"key":"10.1016\/j.bulcan.2026.02.003_bib0235","article-title":"Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol [Internet]"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.003_bib0240","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell [Internet]"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.003_bib0245","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","article-title":"Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol [Internet]"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.003_bib0250","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell [Internet]"},{"key":"10.1016\/j.bulcan.2026.02.003_bib0255","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2022.10.012","article-title":"Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry\u2013based single-cell analysis","volume":"174","author":"Isomoto","year":"2022","journal-title":"Lung Cancer [Internet]"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.003_bib0260","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell [Internet]"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.003_bib0265","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol [Internet]"},{"issue":"21","key":"10.1016\/j.bulcan.2026.02.003_bib0270","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.003_bib0275","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jtho.2025.05.020","article-title":"LEAP-008: lenvatinib plus pembrolizumab for metastatic NSCLC that has progressed after an anti-PD-(L)1 plus platinum chemotherapy","volume":"20","author":"Leighl","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2026.02.003_bib0280","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1200\/JCO.23.02166","article-title":"CONTACT-01: a randomized phase III trial of atezolizumab\u00a0+\u00a0cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.003_bib0285","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.bulcan.2026.02.003_bib0290","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.02.003_bib0295","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2026.02.003_bib0300","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.003_bib0305","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","article-title":"OAO8.05 Tusamitamab Ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: results from phase 3 CARMEN-LC03 trial","volume":"19","author":"Besse","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"25","key":"10.1016\/j.bulcan.2026.02.003_bib0310","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.003_bib0315","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.02.003_bib0320","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bulcan.2026.02.003_bib0325","doi-asserted-by":"crossref","first-page":"101563","DOI":"10.1016\/j.tranon.2022.101563","article-title":"Lung cancer and oncolytic virotherapy\u2013enemy's enemy","volume":"27","author":"Li","year":"2023","journal-title":"Transl Oncol"},{"issue":"4\u20136","key":"10.1016\/j.bulcan.2026.02.003_bib0330","first-page":"187","article-title":"Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations","volume":"13","author":"Sowndharya","year":"2024","journal-title":"Pharm Pat Anal"},{"issue":"suppl_2","key":"10.1016\/j.bulcan.2026.02.003_bib0335","first-page":"482","article-title":"Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.02.003_bib0340","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","article-title":"Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study","volume":"24","author":"Leal","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16_suppl.","key":"10.1016\/j.bulcan.2026.02.003_bib0345","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2024.42.16_suppl.2008","article-title":"Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases","volume":"42","author":"Mehta","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl_2","key":"10.1016\/j.bulcan.2026.02.003_bib0175","first-page":"1","article-title":"Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): a phase Ib\/IIa clinical trial targeting identified resistance pathways","volume":"35","author":"Tomasini","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:39:18Z","timestamp":1777592358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512600144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S000745512600144X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.02.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s et synth\u00e8se du traitement de seconde ligne des CBNPC de stade IV sans addiction oncog\u00e9nique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}